ChatDOC/OCRFlux-pubtabnet-cross · Datasets at Hugging Face (original) (raw)

8972e89bad9919ad83c32b48e7b9e9cd51e4789b2ccabb477e312941d5761c82.png

Parameters

School A

School B

q_c, mean \[ 95 % CI\]

1.39×10⁻² \[ 8.10×10⁻³−2.03×10⁻²\]

1.96×10⁻² \[ 1.11×10⁻²ͨ...

Parameters	School A	School B
qc, mean \[ 95 % CI\]	1.39×10−2 \[ 8.10×10−3−2.03×10−2\]	1.96×10−2 \[ 1.11×10−2−2.89×10−2\]
qg, mean \[ 95 % CI\]	4.36×10−3 \[ 9.61×10−4−8.34×10−3\]	4.61×10−3 \[ 2.98×10−4−1.15×10−2\]

qs, mean \[ 95 % CI\]	9.52×10−4 \[ 2.87×10−4−1.82×10−3\]	2.96×10−3 \[ 1.64×10−3−4.45×10−3\]
ε, mean \[ 95 % CI\]	3.70×10−3 \[ 1.95×10−3−5.69×10−3\]	2.65×10−3 \[ 1.37×10−3−4.20×10−3\]

6c338e811af9402b98f215c9759761bc6c3def789a9ad83789f208d267d0006a.png

Dependent variable

ANC4

SBA

IFD

Density variable

% "urban"

score

% "urban"

score

% "urban"

score

Density

0.003\*\*\*

0.002\*\*

0.004...

Dependent variable

ANC4

SBA

IFD

Density variable

% "urban"

score

% "urban"

score

% "urban"

score

Density

0.003\*\*\*

0.002\*\*

0.004...

Dependent variable

ANC4

SBA

IFD

Density variable

% "urban"

score

% "urban"

score

% "urban"

score

# 4-wheel vehicles, per capita

0.035

0...

8be7af498b313fcdc872c170f32425cebc75098e7c2119ea1b47a88c691245eb.png

Weeks

Daily dose

Niaspan FCT dosage

Initial titration schedule

0 to 4

500 mg

One 500 mg tablet at bedtime

5 to 8

1,000 mg

One 1,000 mg tablet or two 500 mg tablets at bedtime

9 ...

Weeks

Daily dose

Niaspan FCT dosage

Initial titration schedule

0 to 4

500 mg

One 500 mg tablet at bedtime

5 to 8

1,000 mg

One 1,000 mg tablet or two 500 mg tablets at bedtime

9 ...

	Weeks	Daily dose	Niaspan FCT dosage
Initial titration schedule	13 to 24	2,000 mg	Two 1,000 mg tablets at bedtime

60f7079ba6d811dea21e96d519da45548135509ecd489525770ce40514ffb5a0.png

Combination

sensitivity (HCC = 50)

specificity (LC = 41)

TPP

TPN

afp

56.00%

100.00%

100.0%

65.10%

a...

Combination

sensitivity (HCC = 50)

specificity (LC = 41)

TPP

TPN

afp

56.00%

100.00%

100.0%

65.10%

afp+piv

4.82

2.68

2.31

2.15

1.85

1.53

1.46

1.4

1.27

1.24

1.05da8512c3da0b345d6c822eda63edeec3e5bd7bbf92e06c067178beb54447138f.png

Variable

OR^a (IC95%)

p^a value

OR^B (IC95%)

p^b value

PSVI

Part 1

Low PSVI

< 0.01

Variable

ORa (IC95%)

pa value

ORB (IC95%)

pb value

PSVI

Part 1

Low PSVI

< 0.01

Middle PSVI

1.21 (1.21; 1.21)

< 0.01

Variable

ORa (IC95%)

pa value

ORB (IC95%)

pb value

Age group

15–19

1.09 (1.09; 109)

< 0.01

1.04 (1, 1.08)

Part 3

Family income

Hous...

c26a54401dc062f7ff2aff801c23eccf6a5c71206acd06bc029182e31ca1f01d.png

<...

	Group I(n = 25)	Group P(n = 25)	P value
Desaturation (SpO₂ < 90%)	3 (12%)	2 (8%)	1.000
Gastric insufflations	1 (4%)	0 (0%)	1.000
Aspiration

	Group I(n = 25)	Group P(n = 25)	P value
Desaturation (SpO2 < 90%)	3 (12%)	2 (8%)	1.000
Gastric insufflations	1 (4%)	0 (0%)	1.000
Aspiration	0 (0%)	0 (0%)	—
	Group I(n = 25)	Group P(n = 25)	P value
Bronchospasm	0 (0%)	0 (0%)	—
Blood stain	0 (0%)	2 (8%)	0.490

3df4c15b6e133af47b8de862f86279470a08b80f5332c42d7772054da865abf1.png

...

Remaining per-base coverage after B-tail removal	Number of positions with this coverage in the ZR reference (Bv-95nt data)	Number of positions with this coverage in the PhiX reference (PhiX-95nt data)
90 to 100%	41,130 (40.26%)	4,016 (91.65%)

Remaining per-base coverage after B-tail removal

Number of positions with this coverage in the ZR reference (Bv-95nt data)

90 to 100%

41,130 (40.26%)

80 to 90%

4,056 (3.97%)

60 to 80%

1,711 (1.67%)

40 to 6...

Number of positions with this coverage in the PhiX reference (PhiX-95nt data)

4,016 (91.65%)

266 (6.07%)

100 (2.28%)

0 (0.00%)

f8e5e3067d00554e8de86b5f0fc0fd401ea4aa43d2cafca8f83aeb2b3c94593a.png

Parameter

TPC

Antioxidant Capacity

ABTS

DPPH

CUPRAC

p > F

p > <... 18e1b93b8340cf2b853cddc614226757d23d6bdeeef0a3e94530be06efbe04b2.png

Parameter

TPC

Antioxidant Capacity

ABTS

DPPH

CUPRAC

p > F

0.86

0.40

β11

6.65

0.05 \*

7.59

0.04 \*

0.85

0.40

7.26

0.04\*

β22

0.11

0.75

...

903042a25ca43bbf9921d7abf1757d3c6c75af5fb987812cb41cdb01eb670685.png

Medical categories	Number of species	Citations	Fic
Tonic	5	38	0.89
Dermatological	4	120	0.97
Gastrointestinal	32	433	0.92
Galactagogue
Medical categories	Number of species	Citations
Tonic	5	38
Dermatological	4	120
Gastrointestinal	32	433
Galactagogue	8	86
Reproductive
Fic
0.89
0.97
0.92
0.91
0.93
0.89
0.91
0.90
0.85

70bf8d7bdd26521240c6df2c0310cd7ece22e69d598f725caf8d4247d3790079.png

Marker	Peripheral stroma	Central stroma	Anterior stroma	Posterior stroma
ABCG2	−	−	−	−
ABCG5	−	−	−	−
ALDH1A1
Marker	Peripheral stroma	Central stroma	Anterior stroma	Posterior stroma
ABCG2	−	−	−	−
ABCG5	−	−	−	−
ALDH1A1	++	++	++	+
Fibroblast marker	−	−	−	−
Fibronectin	−	−	−	−
Ki-67	−	−	−	−
Nestin	−	−	−	−
VE-Cadherin	−	−

Ezetimibe plus Fenofibrate

Atorvastatin Monotherapy

Baseline

6 Weeks

% Change

p Value

Baseline

6 Weeks

% Change

p Value

% Difference

p Value

Ezetimibe plus Fenofibrate

Atorvastatin Monotherapy

Baseline

6 Weeks

% Change

p Value

Baseline

Total Chol (mmol/L)

5.9

4.4

-25.1

< 0.001

5.8

LDL...

Atorvastatin Monotherapy

6 Weeks

% Change

p Value

% Difference

p Value

4.4

-24.6

< 0.001

-0.4

0.806

2.3

-36.7

< 0.001

2.1

0.4642597d9582fe42683d4bcea786ddf46f1cfbd60f5714f6206a665bd779c02c8f.png

Axis	CoG Position	Linear Acceleration
First Version	Second Version	First Version	Second Version
X	2.4252e−06	1.0008e−06	--\*	--\*
Axi	CoG Position	Linear Acceleration
First Version	Second Version	First Version	Second Version

834c2f9603f4bacecdf442d509f5486e5987a4f4604b79241771b8f8c29329cd.png

s
X	2.4252e−06	1.0008e−06	--\*	--\*
Y	1.3992e−05	1.3390e−05	6.3191e−06	5.1146e−06
Z	1.5306e−05	4.4980e−06	2.7849e−06	2.3104e−06

	Over-expressed in melan-a v B16	Under-expressed in melan-a v B16	Total
Upregulated by RA treatment	71	14	85
Downregulated by RA treatment	16	132	151
Total	87	149

Over-expressed in melan-a v B16

Under-expressed in melan-a v B16

Total

Upregulated by RA treatment	71	14	85
Downregulated by RA treatment	16	132	151
Total	87	149	233

af753c587e401fa38d39ab7e2a29990dd85b9cee68ff289a1ee09396b7077482.png

Characteristics

n (%)

Patient factors

Age (years)

≥ 50

68 (30.9)

< 50

152 (69.1)

Gender

Male

167 (75.9)

Fem...

Characteristics

n (%)

Patient factors

Age (years)

≥ 50

68 (30.9)

< 50

152 (69.1)

Gender

Male

167 (75.9)

Female

53 (24.1...

1	.0)
N2	40 (18.2)
N3	18 (8.2)
Treatment factors
chemotherapy
Yes	190 (86.4)
No	30 (13.6)

1e3d063bd2a22f6d1f3e4a4518b4b8875d54e4ba9ea94bb9cd42726210c2712e.png

Group

Variable

Lambda

DF1

DF2

p-value

SD-Risk

IFN

0.4841

17.5871

< 0.0001

SD-Risk

IL-2

0.3719

27.8637

<...

Group	Variable	Lambda	F	DF1	DF2	p-value
SD-Risk	IFN	0.4841	17.5871	2	33	< 0.0001

...

b8be3d5b9226ae98763531e3cc05f3d194628d6863e351cb90e0558a871369fa.png

Group	Variable	Lambda	F	DF1	DF2	p-value
SD-Risk	IL-2	0.3719	27.8637	2	33	< 0.0001
SD-Risk	IL-10	0.6091	10.5889	2	33	0.0003

line	gene copy number
WT	0
Sox23	6 (12 homozygous)
Sox42	1 (2 homozygous)
Sox44	2 (4 homozygous)

line

Sox23

Sox42

Sox44

gene copy number

6 (12 homozygous)

1 (2 homozygous)

2 (4 homozygous)

3131f597fe5d7c6831f472a1fe5bf587cb8920fc9a4e5c1ef2246381a02416a0.png

Skill 1

Skill 2

Skill 3

Skill 4

Skill 5

Total/Avg

Skill 6

Pre-workshop (n = 12)

3.5

4.3

3.8

2.8

2.3

16.7/3.3

3.5

Post-workshop (n = 7)

4.6

5.0...

Skill 1

Skill 2

Skill 3

Skill 4

Skill 5

Total/Avg

Skill 6

Pre-workshop (n = 12)

3.5

4.3

3.8

2.8

2.3

16.7/3.3

3.5

Post-workshop (n = 7)

4.6

5.0

4.4

4.7

2.6

21.3/4.3

2.0

p-value

<0.01

<0.05

0.18<...

546526ada8af73eb8b1a7608e2cf49686977324b40c7dcd68f7e33b2a3c80b1d.png

8de1285b04d9bbcdbe6075904c78dbbf8d7e09f8685023507e48bd9e45cc227a.png

Index

Placebo group

Zaleplon 10 mg group

Zaleplon 15 mg group

Scores of SQS

3.75 ± 1.04

5.38 ± 0.92^\*\*

6.00 ± 0.76^\*\*

Scores of SDS

3.25 ± 1.04

4.62 ± 1.41^{\*<...

Index Placebo group Zaleplon 10 mg group Zaleplon 15 mg group
Scores of SQS 3.75 ± 1.04 5.38 ± 0.92\*\* 6.00 ± 0.76\*\*

Index Placebo group Zaleplon 10 mg group Zaleplon 15 mg group
Scores of SDS 3.25 ± 1.04 4.62 ± 1.41\* 6.12 ± 0.83\*\*∆
Scores of SSS 2.38 ± 0.92 2.12 ± 0.64 2.38 ± 0.92

a97b1dea321e4959385b0c3c7724ccce8bc379b880263c44c67aba9d2e1544af.png
Characteristic No. of patients %
Patients evaluable 40 100
Age, years
Median 65
Range 34–75
Sex
Characteristic No. of patients %
Patients evaluable 40 100
Age, years
Median 65
Range 34–75
Sex

Characteristic No. of patients %
Male 24 60
Female 16 40
ECOG PS
0 6 15
1 27 67.5
2 7 17....

465f25e16086d4dac57994d374e6e51ddac600e80d821e1de256610b56e32983.png
Patient Karyotype/Molecular lesion(s) FAB subgroup Age at diagnosis IDO1 status CR Relapse Alive
UPN #1 Normal M2 13.0 Negative Yes No Yes
UPN #2 t(8;2...

<...

Patient Karyotype/Molecular lesion(s)
UPN #1 Normal
UPN #2 t(8;21) (q22;q22)
UPN #3 Normal
UPN #4 Normal
UPN #5 Normal
UPN #6 Normal
FAB subgroup Age at diagnosis IDO1 status CR Relapse Alive
M2 13.0 Negative Yes No Yes
M2 13.0 Negative Yes No Yes
M1 10.0108caffb46f5d2d3b9e391f68e12c6627a9f1696d012fc7506f47a279b244189.png
...

Sock-only Shod
Subject r nMAD r nMAD
1 0.91 0.09 0.59 0.23
2 0.77 0.16 0.56 0.22
3 0.84...

Sock-only Shod
Subject r nMAD r nMAD
1 0.91 0.09 0.59 0.23
2 0.77 0.16 0.56 0.22
3 0.84
5 0.79 0.16 0.39 0.27
6 0.92 0.1 0.87 0.12
7 0.85 0.14 0.83 0.13
8 0.92 0.09 0.8 0.15
9 0.65 ...

1bb88fd1455395a16cff183d37599c390cee3b1b0af5930f889f36b37f061cb2.png
61015fa3438e3f6f3d7105aace6b5df60ab2f5d3acb3e7632bfe8dd12c07e5c0.png
Patient Before 2 months 6 months 1 year
Right^a Left^b Right Left Right Left Right Left

Patient Before 2 months 6 months 1 year
Righta Leftb Right Left Right Left Right Left
Biceps brachii m...

12 0.00 0.00 0.00 0.00 0.00 0.00 0.51 0.42
14 0.55 0.00 0.62 0.38 2.14 1.39 1.07 0.66
16 0.00 0.00 0.85 0.761add04ad3d4466031d7bdd5af31027c428a1c6f028242e592dba1e3960a1317a.png
<...

Age range Count^a ERP^b Rate^c Ratio^d 95 % CI
4 7,594 72,820 10.4 0.26 0.26 0.26
5–9 100,787 340,503
Age range Counta ERPb Ratec Ratiod 95 % CI
4 7,594 72,820 10.4 0.26 0.26 0.26
5–9 100,787 340,503 29.6 0.74 0.74 0.74
31779a6c73bacce3fe6e376a74314056faa235bb6555c4b932c17ea33e7da319.png
10–14 132,965 330,448 40.2 1 1 1
15–19 81,910 355,117 23.1 0.57 0.57 0.57
20–24 47,831 412,009 11.6 0.29 0.29 0.29
Patients withAlzheimer's disease (n=21) Patients withfrontotemporal dementia (n=23) U Z p\*
M±SD CI 95% M±SD CI 95%
Patients withAlzheimer's disease (n=21) Patients withfrontotemporal dementia (n=23) U Z p\*
M±SD CI 95% M±SD CI 95%
Patients withAlzheimer's disease (n=21) Patients withfrontotemporal dementia (n=23) U Z p\*
M±SD CI 95% M±SD CI 95%

Concentration range (pg/g lipid) Second-order (equivalent to minus change in apparent elimination rate in 2006) First-order (equivalent to minus apparent elimination rate)
coefficient p-value coefficient <...

Concentration range (pg/g lipid) Second-order (equivalent to minus change in apparent elimination rate in 2006) First-order (equivalent to minus apparent elimination rate)
coefficient p-value coefficient p-value<...

Concentration range (pg/g lipid) Second-order (equivalent to minus change in apparent elimination rate in 2006) First-order (equivalent to minus apparent elimination rate)
coefficient p-value coefficient p-value<...

b82b74ede38db7487e6946fe4c11597b8ba733ef06042b74b49534376e8bcebe.png
N = 1352 Non-responders n = 909 Responders n = 443 p value
Women, n (%) 520 (57) 273 (62) 0.12 A
Age, average years (SD) 41.3 (11.8) 44.4 (10.8) 0.05 B
N = 1352 Non-responders n = 909 Responders n = 443 p value
Women, n (%) 520 (57) 273 (62) 0.12 A
Age, average years (SD) 41.3 (11.8) 44.4 (10.8) 0.05 B
Work n (%)
N = 1352 Non-responders n = 909 Responders n = 443
Non-RTW 309 (34) 146 (33)
RTW 548 (60) 273 (62)
Old age and disability pension 50 (6) 22 (5)
Died 2 (0) 2 ...

aa44cf6c3f9a961ef2307e446b7253cab3fc474c2e7a9ad91b1d682d92c8efb9.png
...

Perianal disease prior to pregnancy n = 27 No perianal disease prior to pregnancy n = 87
Mode of childbirth Vaginal delivery n (%) Caesarean section n (%) Vaginal delivery n (%) Caesarean section n (%)
...

Perianal disease prior to pregnancy n = 27 No perianal disease prior to pregnancy n = 87
Mode of childbirth Vaginal delivery n (%) Caesarean section n (%) Vaginal delivery n (%) Caesarean section n (%)
Progression perianal disease ≤ 2 years post partum: 2 (18) 5 (31) 3 (5) 3 (14)
- Yes 9 (82) 9 (56) 58(94) 18 (86)
- No 0 (0) 2 (13) 5 (1) 0 (0)
- Not applicab...

21d214ad1e4e3238c3aa6ad4b4b716adae35e514a724e799de69cc970660cfc4.png
Peptide Sequence Mw pI¹ Net charge Mean hydrophobicity²
KHN20 KHNLGHGHKHERDQGHGHQR 2365.5 9.99 +2 −4.91
GHG20 GHGLGHGHEQQHGLGHGHKF 2127.2 7...

Peptide Sequence Mw
KHN20 KHNLGHGHKHERDQGHGHQR 2365.5
GHG20 GHGLGHGHEQQHGLGHGHKF 2127.2
GHG21 GHGHKFKLDDDLEHQGGHVLD 2354.5
GGH20 GGHVLDHGHKHKHGHGHGKH 2169.3<...

pI1 Net charge Mean hydrophobicity2
9.99 +2 −4.91
7.21 0 −2.01
5.63 −3 −2.32
9.70 +2 −3.44
10.78 +7 −5.91
1...

483d9bc63d82a56209d473d293ba38f1616315880c3d6c1e42c576e119a41735.png
Matching phase Type of match Number linked %
1 Child’s first, middle, and last name & dob and mother’s dob 5282 2.6 %
2 Child’s first, middle initial, and last name & dob and mother’s...

Matching phase Type of match Number linked %

1 Child’s first, middle, and last name & dob and mother’s dob 5282 2.6 %
2 Child’s first, middle initial, and last name & dob and mother’s dob 32094 16.0 %
3 Child’s first, middle, and last name & dob 30351c8c786e697d73021eaa53b2981f842209367d6595154fc3c3110bd98e9f27e0.png
Number Authors, year c Age, sex Period (years) symptoms Preoperative lab Treatment Histological diagnosis Outcomes
1 Boriani et al, 1978 \[8\] S1-3 18, M DNMI Bone pain, weakness...

Number Authors, year c Age, sex Period (years) symptoms Preoperative lab
1 Boriani et al, 1978 \[8\] S1-3 18, M DNMI Bone pain, weakness Hypophosphatemia, elevated ALP
2
Treatment Histological diagnosis Outcomes
Complete resection, radiotherapy Osteosarcoma NOLF
Complete resection, supplementation of vitamin D, phosphate, and calcium Neuroendocrine tumor NOLF
Partial resect...

1d6c6d54bc931bbc726f4d9068f717a7b7a9bc930cefed5207aa0fa6357472e4.png
Antibiotics^a Extracts concentration^b Bacteria, MIC (μg/mL) and modulating factors (in bracket) Modulating effect (%)^b
E. coli E. aerogen...

Antibioticsa Extracts concentrationb Bacteria, MIC (μg/mL) and modulating factors (in bracket) Modulating effect (%)b
E. coli E. aerogenes K. pneumoniae P. stuartuii
CIP MIC/2 ≤0.5 (na) ≤0.5 (na) 64(2) 32 (2) 128 (1) 1 (1) 64 (2) 1 (1) 32 (1) 33.33
MIC/4 ≤0.5 (na) ≤0.5 (na) 128(1) 64 (1) 128 (1) 1 (1)8d262637ec2bd2cf4019abcbcb92951ebf038969a6655cc8d7cabf530861342b.png
<...

Period No. of regions STR-realigner ReviSTER IndelRealigner --realign option Original BAM
1 5345 2.477 2.695 6.017 6.009 6.009
2 1160
Period No. of regions STR-realigner ReviSTER IndelRealigner --realign option Original BAM
1 5345 2.477 2.695 6.017 6.009 6.009
2 1160 3.545 3.740
Total 9595 3.116 3.309 6.752 6.727 6.732

2314ae9f3cbe088777a86993d3c7863ec9dae7b4e78a27677351688d054de18a.png
Variables β P value OR (95% CI)
Age 0.428 <0.001 1.53 (1.35–1.75)
HR 0.859 <0.001 2.36 (2.09–2.67)
BMI 0.273 0.001 1.31 (...

...

c2f55c30d3aa8f10229f888d93310dd098f4d07dc90803f295703f636a2c0e04.png
Variables β P value OR (95% CI)
Age 0.428 <0.001 1.53 (1.35–1.75)
HR 0.859 <0.001 2.36 (2.09–2.67)
BMI 0.273 0.001 1.31 (1.13–1.53)
WC
DBP 0.019 0.001 1.02 (1.01–1.03)
FPG 0.450 <0.001 1.57 (1.39–1.78)
PBG 0.475 <0.001 1.61 (1.41–1.83)
IR 0.279 <0.001 1.32 (1.20–1.46)
TG
Year
1992 (n = 321) 2000 (n = 433) 2008 (n = 607) Trend
% n % n % <...

Year
1992 (n = 321) 2000 (n = 433) 2008 (n = 607) Trend
% n % n % n χ2 (d.f. = 1) P
Year
Bad news 76 94 73 74 48 91 26.653 < 0.001
Understanding mental illness 6 8 14 14 24 45 17.096 < 0.0...

cb17a289922844333b0e6ca44260abc1cb959f2d067264fa51a35124da008bba.png
Trait (nm) Standard diet Standard diet + ATRA
SHR SHR-Lx SHR SHR-Lx
(n = 7) (n = 7) (n = 7) (n = 8)
VLDL-TG 49.51 ± 0....

Trait (nm) Standard diet Standard diet + ATRA

Trait (nm) SHR SHR-Lx SHR SHR-Lx
(n = 7) (n = 7) (n = 7) (n = 8)
VLDL-TG 49.51 ± 0.45 48.24 ± 0.49 48.48 ± 0.68 50.27 ± 0.41\*,a
LDL-C 21.45 ± 0.25}

Method of risk assessment

Definition

Advantages

Limitations

Clinical prediction rules

The use of a scoring system based on patient- or procedure-related risk factors to quantify risk

Often cost-neutral

Estimates population risk for patient ...

Method of risk assessment

Definition

Advantages

Limitations

Clinical prediction rules

The use of a scoring system based on patient- or procedure-related risk factors to quantify risk

Often cost-neutral

Estimates population risk for patient ...

Method of risk assessment

Definition

Advantages

Limitations

Poor sensitivity and specificity for prediction of morbidity and mortality on an individual patient basis\[33,40\]

Lee Revised Cardiac Risk Index (RCRI)

S...

7dbae20bf417d120566efbf5e1069658b3102a91265d7544a4148bd8ea269ba7.png

Polymorphism

Reference allele homozygote

Heterozygote

Variant allele homozygote

PAI-2 (SERPINB, rs6095)

Event Rate (%)

34.7

14.6

6.7

Number of patients

4... <...

Polymorphism	Reference allele homozygote	Heterozygote	Variant allele homozygote
PAI-2 (SERPINB, rs6095)
Event Rate (%)	34.7	14.6	6.7
Number of patients	72	48

Number of patients (%)

67.9

29.3

2.9

CETP (CETP, rs708272)\*

Event Rate (%)

14.9

26.4

33.3

Number of patients

Number of patients (...

c790e2463e5e7b3dfcb06fd98a5c88fd693e3ca1e91ce2133f2d1e9ba2d18483.png

...

Group	Location	Gender	Age range (years)	Number of participants
One	ROI	Female	20-29	8
Two	ROI	Female	30-40	9
Three	ROI	Male	29-39

Group	Location	Gender	Age range (years)	Number of participants
One	ROI	Female	20-29	8

9719396d944e667711b48e627cccebac09e62229ec8e1450c5732639d36c45bf.png

Group	Location	Gender	Age range (years)	Number of participants
Two	ROI	Female	30-40	9
Three	ROI	Male	29-39	8
Four	NI	Male	29-59

Gene/Gene Cluster Name

Localization within the POC9 Draft Genome Sequence(GenBank acc. no.)

Protein

Best BLAST Hits:\[% Identity\] Organism(GeneBank acc. no.)

Predicted Antimicrobial Resistance Profile

Tested Antibiotics

Profile

<...

Gene/Gene Cluster Name

Localization within the POC9 Draft Genome Sequence(GenBank acc. no.)

Protein

Best BLAST Hits:\[% Identity\] Organism(GeneBank acc. no.)

Predicted Antimicrobial Resistance Profile

Tested Antibiotics

Profile

g...

tetG-tetR

contig00014 (QGST01000014.1)coordinates: 7148–9063

Tet(A/B/C) family MFS transporter

\[87%\] Ochrobactrum oryzae(WP\_104755825)

tetracyclines

transcriptional regulator ...

6aa169f9d5fbada5f015c1d047606c96fbc7b18a28eeeefc48feb4f09b4b2aa7.png

Fixed effects model

Growth curve model 1

Growth curve model 2

Fixed part

Intercept

0.820 (0.756 to 0.884)

0.823 (0.779 to 0.866)

0.830 (0.791 to 0.87)

Age-centred (li... ccaa30b2b79fc120081d5d0f41702613b88cac6b56335baac2ee9126bd902fbb.png
Fixed effects model Growth curve model 1 Growth curve model 2
Fixed part
Intercept 0.820 (0.756 to 0.884) 0.823 (0.779 to 0.866) 0.830 (0.791 to 0.87)
Age-centred (linear term)
Fixed effects model Growth curve model 1 Growth curve model 2
Level 1 (wave)
Intercept 0.020 0.020
N observations (level 1) 27 509 27 509 27 509
Characteristic N %
Age
< = 50 22 13.3
51-60 42 25.3
61-70 57 34.3
> 70 45 27.1
Tumor (T) ...
Characteristic
Age
< = 50
51-60
61-70
> 70
Tumor (T)
T1
T2
T3
T4
Lymph nodes (N)
N0
... <...
79e181aa93eba88ac222ea123cb792b90ecdc7862e5cfb598ead0256edc4904b.png
N %
22 13.3
42 25.3
57 34.3
45 27.1
68 41
40 24.1
34 20.5

Month 1 Month 16 Month 21 Total samplen = 72
Decisions to be made, n (%)
Medical admission or treatment 17 (81)^a 12 (44)^a 8 (33)^a
Month 1 Month 16 Month 21 Total samplen = 72
Decisions to be made, n (%)
Medical admission or treatment 17 (81)a 12 (44)a 8 (33)a 37 (51)
Psychiatric adm...
Month 1 Month 16 Month 21 Total samplen = 72
Agreement status, n (%)
Agreeing 5 (24) 15 (56) 12 (50) 32 (44)
Not agreeing(or unable to express a choice/n...
81ee06e3d49c6d5e79b5b0194793bb6f3dff718b95f0d6bd127275843a7cac92.png

Food composition of major foods in Uganda (per 100 g of edible portion)
Food Calories Protein (g) Iron (Mg)
Finger millet 346 8.7 4.0
Sorghum 354 10.2
Food composition of major foods in Uganda (per 100 g of edible portion)
Food Calories Protein (g) Iron (Mg)
Finger millet 346 8.7 4.0
Sorghum 354 10.2
Simsim 593 20.1 9.8
Sweet Potato 166 1.3 1.2
Per capita of protein and calories derived from the major foods
Food Protein Calories...
e671671fe066e5733268260f13cb36a8277c039eaccccd5b61f626a78359a3a7.png

Cluster # Expression level
High Medium high Medium Medium low Low
1 Ribosome Lumen Lumen Lumen DNA repair/Stress response
2 Oxidative Phosphor...
Cluster # Expression level
High Medium high Medium Medium low Low
1 Ribosome Lumen Lumen Lumen DNA repair/Stress response
2 Oxidative Phosphor...
al subunits components Ankyrin repeats ion of differentiation
10 Protein folding RNA splicing tRNA Zinc finger CH2 Nucleic acid binding

1760b2a9a980613cd0d31f0518c69959cd5abeae1a41b7c004ec897f66ae1127.png

Primary reference, Study, Country (secondary references) Objectives Design Sample size Patient population Follow-up
Treatment-related observational studies
Driessen 2008\[68\], Radboud University Registry, The Netherlands...
Primary reference, Study, Country (secondary references) Objectives Design Sample size Patient population Follow-up
Treatment-related observational studies
Driessen 2008\[68\], Radboud University Registry, The Netherlands...
Primary reference, Study, Country (secondary references) Objectives Design Sample size Patient population Follow-up
Kane 2003\[95\], St. Vincent's University study, Ireland, (Kane 2003a\[96\]) Clinical presentation, outcome and prognosis of ear...
e9b63f146dc955559d16fe04f4b008cc06ff86cee61a0a6a21294f06ccd8332c.png

Characteristics No OSA Mild-Moderate OSA Severe OSA p value
n = 10 n = 33 n = 34
Total sleep time (minutes) 288.2 ± 88.2 268.3 ± 80.7 253... ...
ecaa3f8b2afd8c6029196955bef614115131d03d423e995bc8434738abd43359.png
Characteristics No OSA Mild-Moderate OSA Severe OSA p value
n = 10 n = 33 n = 34
Total sleep time (minutes) 288.2 ± 88.2 268.3 ± 80.7 253.8 ± 74.6 0.207
Sleep efficiency (%) 76.1 ± 22.9 75.8 ± 16.1 72.1 ± 18.0 0.506
AHI event. h−1 2.4 ± 1.5 16.2 ± 6.6 61.4 ± 20.0 0.001
ODI event. h−1 1.7 ± 1.7 14.5 ± 6.1 52.1 ± 22.8 0.001
Animal group Body weight (g) Blood glucose (mg/dL)
Before STZ injection End experiment Before drug injection End experiment
Control (8) 270 ± 13.9 276.25 ± 13.29
Animal group Body weight (g) Blood glucose (mg/dL)

Animal group Before STZ injection End experiment Before drug injection End experiment
Control (8) 270 ± 13.9 276.25 ± 13.29 133 ± 33.41 132.87 ± 35.62
Vehicle (8) 260 ± 21.60 237.14 ± 24.97\*<...
0f11f0c50f89213400914c7a505147442058b668589b9430ede7aef5c13d8c07.png

Symbol Name Function Reference
PLK1 polo-like kinase 1 cell cycle regulation \[13-19\]
CDK16 cyclin-dependent kinase 16 cell cycle regulation \[20\]
RYK receptor-like tyrosine ki...
Symbol Name Function Reference
PLK1 polo-like kinase 1 cell cycle regulation \[13-19\]
CDK16 cyclin-dependent kinase 16 cell cycle regulation \[20\]
RYK receptor-like tyrosine ki...
Symbol Name Function Reference
AURKA aurora kinase A cell cycle regulation \[33,34\]
BUB1 mitotic checkpoint serine/threonine kinase cell cycle regulation \[35\]
CDC7 cell divisi...
8a938dcf98995c1cad36b196933af6ea2d61f6576d11c00cb0996bf830a2545c.png

Dietary supplementation^a Statistical significance of variance ratio (P)^b, effects of
Control TTA FO TTA + FO TTA FO TTA\*FO
CPT-I 2....
Dietary supplementationa Statistical significance of variance ratio (P)b, effects of
Control TTA FO TTA + FO TTA FO TTA\*FO
CPT-I 2.79 ± 0.26c 1.69 ±... <...
85dbd38e4c22fe34329f26898b167873c62a81dece6b75b27f9de01171c94c2d.png
CPT-I (with malonyl-CoA) 1.89 ± 0.21 1.23 ± 0.28 1.77 ± 0.14 1.31 ± 0.13 <0.001 0.73 0.14
CPT-II 10.79 ± 1.03 23.55 ± 3.15 12.40 ± 2.33 22.39 ± 4.32 <0.001 0.82 0.15

...
2e223de9d2a4188ea3d600f4da5d81bb8f015ad92f14d270ecae7d7ae159a10a.png
D-dimer ≥10 μg/mL after treatment
No Yes p^∗
(n = 31) (n = 21)
Male sex 18 (58.1%) 10 (47.6%)
D-dimer ≥10 μg/mL after treatment
No Yes p∗
(n = 31) (n = 21)
Male sex 18 (58.1%) 10 (47.6%) 0.458
Age, years 63 (55–71)
D-dimer ≥10 μg/mL after treatment
No Yes p∗
(n = 31) (n = 21)
Warfarin 10 (32.3%) 16 (72.6%)
Cancer profiles
Generic name Study drug name (Brand name) Active ingredient content Manufacturers/distributors
amlodipine besilate Amlodin^®tablets 2.5 containing 2.5 mg of amlodipine Sumitomo Pharmaceuticals Co., Ltd.
Generic name Study drug name (Brand name) Active ingredient content Manufacturers/distributors
amlodipine besilate Amlodin® tablets 2.5 containing 2.5 mg of amlodipine Sumitomo Pharmaceuticals Co., Ltd.

Amlodin® tablets 5 containing 5 mg of amlodipine
Norvasc® tablets 2.5 mg containing 2.5 mg of amlodipine Pfizer Japan Inc.
Norvasc® tablets 5 mg containing 5 mg of amlodipine

0a9d75ddd91445ba6a219610e77e40ee6bf6ebcc81a85cc7e82d45983f98cc04.png

BPG Patient Eligibility Criteria Participating Program Units
Asthma Patients who present to the participating units with a primary or secondary diagnosis of asthma Emergency, in-patient and medical units
Breastfeeding Postpartum w...
BPG Patient Eligibility Criteria Participating Program Units
Asthma Patients who present to the participating units with a primary or secondary diagnosis of asthma Emergency, in-patient and medical units

BPG Patient Eligibility Criteria Participating Program Units
Breastfeeding Postpartum women and their infants with a singleton birth, gestational age of 37 or more weeks, hospital length of stay for mother and infant 24 hours or more after birth, infant not delive...
912b9b91fdaca3c74a75ca6d1cb893ea7d8a60f1059bd1b71d4691632ce9fa0d.png

Organism Precision Recall F-score
Mouse 0.77 0.81 0.79
Yeast 0.97 0.84 0.90
Fly 0.83 0.80 0.82
FlyAccept matches of synonyms associated to up...
Organism Precision Recall F-score

Mouse 0.77 0.81 0.79
Yeast 0.97 0.84 0.90
Fly 0.83 0.80 0.82
FlyAccept matches of synonyms associated to up to 3 different Entrez Gene entries 0.74 0.83 0.79<...
e65e582dc802d0364c209deb4409969b2d88f0a20ace377494eb5d13d4fcd674.png

Command Value Description
ACK 0×06 It is sent when a frame has been received and decoded correctly.
NACK 0×15 It is sent when a frame has not been decoded correctly.
RESET 0×08
Command Value Description
ACK 0×06 It is sent when a frame has been received and decoded correctly.

NACK 0×15 It is sent when a frame has not been decoded correctly.
RESET 0×08 It forces the node to be reset. After this command, the node sends an ACK and resets itself. For the next 2 seconds the node enters a programing mode which allows the central comp...
f004dd934af35ecfb12802de9b2f588aa0c04d668fb47d61fd9ad800a4cba792.png

N % % susceptible TMP/SMX Ciprofloxacin Nitrofurantoin
E. coli 73 82 93 100 95
P. mirabillis 5 5.6 100 100 na
K. pne...
N % % susceptible TMP/SMX Ciprofloxacin Nitrofurantoin
E. coli 73 82 93 100 95
P. mirabillis 5 5.6 100 100 na
K. pneumonia 4<...
Total 89 100

228a830e40b5d378aff210113a9bb0879ffd29faf1451bf619922c3ee1867680.png

Dimension Categories
Primary diagnosis Organic mental health problem (most commonly dementia)
Depression or anxiety
Other mental health problem e.g., schizophrenia
Main reason for admission
Dimension Categories
Primary diagnosis Organic mental health problem (most commonly dementia)
Depression or anxiety
Other mental health problem e.g., schizophrenia
Main reason for admission
Main reason for admission Behaviour management related i.e., need for behaviour management, risk of harming others or care breakdown
Need for diagnostic assessment, medication review or treatment
Challenging behaviour Low (behaviou...